Clinical Trials
376 trialsCOM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
IFM2005-02
University Hospital, Toulouse
IFM/DFCI2009
University Hospital, Toulouse
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
BRUOG-407
Brown University
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
EREVA
Centre Hospitalier Régional d'Orléans
IFM 2005-03
Hospices Civils de Lyon
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
PCD
Institut Curie
Stem Cell Transplantation for Patients With Multiple Myeloma
University of Chicago
Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
University of Rochester
MYELAXAT
University Hospital, Grenoble
Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT
Case Comprehensive Cancer Center
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Thomas Jefferson University
Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Hospital Universitario Dr. Jose E. Gonzalez
Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
Emory University
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma
University of Rochester
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Wake Forest University Health Sciences
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Peter MacCallum Cancer Centre, Australia
MargheRITA
Advice Pharma Group srl
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
LYMPHOLD
University Hospital, Toulouse
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Astex Pharmaceuticals, Inc.
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
M.D. Anderson Cancer Center
Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide
Amsterdam UMC, location VUmc
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
MUKtwelve
University of Leeds
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
Stem Cell Translpantation in Multiple Myeloma
European Society for Blood and Marrow Transplantation
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Canadian Cancer Trials Group
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Eastern Cooperative Oncology Group
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Eastern Cooperative Oncology Group
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
Eastern Cooperative Oncology Group
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PAMAL
Insel Gruppe AG, University Hospital Bern
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Genentech, Inc.
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
H. Lee Moffitt Cancer Center and Research Institute